Perioperative NALIRIFOX in patients with resectable pancreatic ductal adenocarcinoma : The open-label, multicenter, phase II nITRO trial
Copyright © 2023 The Authors. Published by Elsevier Ltd.. All rights reserved..
BACKGROUND: Upfront surgery followed by postoperative treatment is a commonly adopted treatment for resectable pancreatic ductal adenocarcinoma (rPDAC). However, the risk of positive surgical margins, the poor recovery that often impairs postoperative treatments, and the risk of recurrence might limit the outcome of this strategy. This study evaluated the safety and the activity of liposomal irinotecan 50 mg/m2 + 5-fluorouracil 2400 mg/m2 + leucovorin 400 mg/m2 + oxaliplatin 60 mg/m2 (NALIRIFOX) in the perioperative treatment of patients with rPDAC.
METHODS: Eligible patients had a rPDAC with < 180° interface with major veins' wall. Patients received 3 cycles before and 3 cycles after resection with NALIRIFOX, days 1 and 15 of a 28-day cycle. The primary endpoint was the proportion of patients undergoing an R0 resection.
RESULTS: 107 patients began preoperative treatment. Nine patients discontinued the treatment because of related or unrelated adverse events. Disease-control rate was 92.9%. 87 patients underwent surgical exploration, 11 had intraoperative evidence of metastatic disease, and 1 died for surgical complications. R0 resection rate was 65.3%. 49 patients completed the three postoperative cycles. The most common grade ≥ 3 adverse events were diarrhea and neutropenia. Median overall survival (OS) of ITT patients was 32.3 months (95% CI 27.8-44.3). Median disease-free and OS from surgery of resected patients were 19.3 (95% CI 12.6-34.1) and 40.3 months (95% CI 29-NA), respectively.
CONCLUSION: Perioperative NALIRIFOX was manageable and active, and deserves further investigation in randomized trials comparing it with standard upfront surgery followed by adjuvant therapy.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 2023 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:196 |
|---|---|
| Enthalten in: |
European journal of cancer (Oxford, England : 1990) - 196(2023) vom: 01. Jan., Seite 113430 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Melisi, Davide [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 18.12.2023 Date Revised 18.12.2023 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.ejca.2023.113430 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM364868570 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM364868570 | ||
| 003 | DE-627 | ||
| 005 | 20231227133752.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.ejca.2023.113430 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1231.xml |
| 035 | |a (DE-627)NLM364868570 | ||
| 035 | |a (NLM)37995598 | ||
| 035 | |a (PII)S0959-8049(23)00732-3 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Melisi, Davide |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Perioperative NALIRIFOX in patients with resectable pancreatic ductal adenocarcinoma |b The open-label, multicenter, phase II nITRO trial |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 18.12.2023 | ||
| 500 | |a Date Revised 18.12.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2023 The Authors. Published by Elsevier Ltd.. All rights reserved. | ||
| 520 | |a BACKGROUND: Upfront surgery followed by postoperative treatment is a commonly adopted treatment for resectable pancreatic ductal adenocarcinoma (rPDAC). However, the risk of positive surgical margins, the poor recovery that often impairs postoperative treatments, and the risk of recurrence might limit the outcome of this strategy. This study evaluated the safety and the activity of liposomal irinotecan 50 mg/m2 + 5-fluorouracil 2400 mg/m2 + leucovorin 400 mg/m2 + oxaliplatin 60 mg/m2 (NALIRIFOX) in the perioperative treatment of patients with rPDAC | ||
| 520 | |a METHODS: Eligible patients had a rPDAC with < 180° interface with major veins' wall. Patients received 3 cycles before and 3 cycles after resection with NALIRIFOX, days 1 and 15 of a 28-day cycle. The primary endpoint was the proportion of patients undergoing an R0 resection | ||
| 520 | |a RESULTS: 107 patients began preoperative treatment. Nine patients discontinued the treatment because of related or unrelated adverse events. Disease-control rate was 92.9%. 87 patients underwent surgical exploration, 11 had intraoperative evidence of metastatic disease, and 1 died for surgical complications. R0 resection rate was 65.3%. 49 patients completed the three postoperative cycles. The most common grade ≥ 3 adverse events were diarrhea and neutropenia. Median overall survival (OS) of ITT patients was 32.3 months (95% CI 27.8-44.3). Median disease-free and OS from surgery of resected patients were 19.3 (95% CI 12.6-34.1) and 40.3 months (95% CI 29-NA), respectively | ||
| 520 | |a CONCLUSION: Perioperative NALIRIFOX was manageable and active, and deserves further investigation in randomized trials comparing it with standard upfront surgery followed by adjuvant therapy | ||
| 650 | 4 | |a Multicenter Study | |
| 650 | 4 | |a Clinical Trial, Phase II | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Liposomal irinotecan | |
| 650 | 4 | |a NALIRIFOX | |
| 650 | 4 | |a Perioperative treatment | |
| 650 | 4 | |a Resectable pancreatic ductal adenocarcinoma | |
| 650 | 7 | |a Fluorouracil |2 NLM | |
| 650 | 7 | |a U3P01618RT |2 NLM | |
| 650 | 7 | |a Irinotecan |2 NLM | |
| 650 | 7 | |a 7673326042 |2 NLM | |
| 650 | 7 | |a Leucovorin |2 NLM | |
| 650 | 7 | |a Q573I9DVLP |2 NLM | |
| 700 | 1 | |a Zecchetto, Camilla |e verfasserin |4 aut | |
| 700 | 1 | |a Merz, Valeria |e verfasserin |4 aut | |
| 700 | 1 | |a Malleo, Giuseppe |e verfasserin |4 aut | |
| 700 | 1 | |a Landoni, Luca |e verfasserin |4 aut | |
| 700 | 1 | |a Quinzii, Alberto |e verfasserin |4 aut | |
| 700 | 1 | |a Casalino, Simona |e verfasserin |4 aut | |
| 700 | 1 | |a Fazzini, Federica |e verfasserin |4 aut | |
| 700 | 1 | |a Gaule, Marina |e verfasserin |4 aut | |
| 700 | 1 | |a Pesoni, Camilla |e verfasserin |4 aut | |
| 700 | 1 | |a Casetti, Luca |e verfasserin |4 aut | |
| 700 | 1 | |a Esposito, Alessandro |e verfasserin |4 aut | |
| 700 | 1 | |a Marchegiani, Giovanni |e verfasserin |4 aut | |
| 700 | 1 | |a Piazzola, Cristiana |e verfasserin |4 aut | |
| 700 | 1 | |a D'Onofrio, Mirko |e verfasserin |4 aut | |
| 700 | 1 | |a de Robertis, Riccardo |e verfasserin |4 aut | |
| 700 | 1 | |a Gabbrielli, Armando |e verfasserin |4 aut | |
| 700 | 1 | |a Bernardoni, Laura |e verfasserin |4 aut | |
| 700 | 1 | |a Crino, Stefano F |e verfasserin |4 aut | |
| 700 | 1 | |a Pietrobono, Silvia |e verfasserin |4 aut | |
| 700 | 1 | |a Luchini, Claudio |e verfasserin |4 aut | |
| 700 | 1 | |a Aliberti, Camillo |e verfasserin |4 aut | |
| 700 | 1 | |a Martignoni, Guido |e verfasserin |4 aut | |
| 700 | 1 | |a Milleri, Stefano |e verfasserin |4 aut | |
| 700 | 1 | |a Butturini, Giovanni |e verfasserin |4 aut | |
| 700 | 1 | |a Scarpa, Aldo |e verfasserin |4 aut | |
| 700 | 1 | |a Salvia, Roberto |e verfasserin |4 aut | |
| 700 | 1 | |a Bassi, Claudio |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t European journal of cancer (Oxford, England : 1990) |d 1991 |g 196(2023) vom: 01. Jan., Seite 113430 |w (DE-627)NLM012602779 |x 1879-0852 |7 nnns |
| 773 | 1 | 8 | |g volume:196 |g year:2023 |g day:01 |g month:01 |g pages:113430 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.ejca.2023.113430 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 196 |j 2023 |b 01 |c 01 |h 113430 | ||